- Conditions
- Prostate Cancer
- Interventions
- 3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
- Radiation · Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fairway, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 431
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 58
- States / cities
- Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Adipose Tissue, Microbiome, Menopause
- Interventions
- GnRHag
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Menopause, Obesity
- Interventions
- Leuprolide acetate
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Prostate Cancer
- Interventions
- leuprolide acetate
- Drug
- Lead sponsor
- GP-Pharm
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more
- Conditions
- Hypogonadism, Precocious Puberty
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 7 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1993
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Insulin Resistance, Postmenopause
- Interventions
- metformin, leuprolide injection, placebo pill, placebo injection
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years to 79 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1454
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Zin W Myint
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- exemestane, tamoxifen, triptorelin
- Drug
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Network
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 2,672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 139
- States / cities
- Burbank, California • La Jolla, California • Mission Hills, California + 106 more
- Conditions
- Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia
- Interventions
- kisspeptin 112-121, GnRH
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Cabozantinib, Androgen Ablation Therapy
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab emtansine, Treatment of physician's choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 59
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab, Leuprolide, Goserelin, Degarelix
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Biospecimen Collection, Computed Tomography, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, ADT, Abiraterone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Triptorelin Pamoate, placebo
- Drug · Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 9 Years to 21 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Prostate Cancer
- Interventions
- Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
- Radiation · Drug
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 106
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
- Interventions
- Abiraterone, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib
- Drug · Radiation · Biological
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Obesity, Fertility
- Interventions
- LOVAZA, GnRH
- Dietary Supplement · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Newly Diagnosed Oligometastatic Prostate Cancer
- Interventions
- radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone
- Procedure · Radiation · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Long Beach, California • West Los Angeles, California • Richmond, Virginia
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
- Drug · Biological · Other + 1 more
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • New Brunswick, New Jersey